Is Maintenance Therapy for Everyone?
Nooka AK et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S139-44. doi: 10.1016/j.clml.2016.02.011.
How to Think About Risk in Myeloma.
Krishnan A. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S135-8. doi: 10.1016/j.clml.2016.02.015.
Clonal Evolution in Multiple Myeloma.
Fakhri B et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S130-4. doi: 10.1016/j.clml.2016.02.025.
Concise review: Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Kint N et al. J Geriatr Oncol. 2016 Aug 23. pii: S1879-4068(16)30103-5. doi: 10.1016/j.jgo.2016.08.001. [Epub ahead of print].
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Kumar S et al. Lancet Oncol. 2016 Aug;17(8):e328-46. doi: 10.1016/S1470-2045(16)30206-6.
Myeloma minimal residual disease testing in the United States: Evidence of improved standardization.
Salem D et al. Am J Hematol. 2016 Aug 24. doi: 10.1002/ajh.24540. [Epub ahead of print].
The immunotherapy era of myeloma: monoclonal antibodies, vaccines and adoptive T cell therapies.
Hoyos V et al. Blood. 2016 Aug 9. pii: blood-2016-05-636357. [Epub ahead of print].
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.
Magen H et al. Ther Adv Hematol. 2016 Aug;7(4):187-95. doi: 10.1177/2040620716652862. Epub 2016 Jun 10.
Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States.
Costa LJ et al. Cancer. 2016 Aug 22. doi: 10.1002/cncr.30183. [Epub ahead of print].
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Thumallapally N et al. Onco Targets Ther. 2016 Aug 5;9:4843-58. doi: 10.2147/OTT.S110189. eCollection 2016.
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S et al. Expert Opin Biol Ther. 2016 Aug 17:1-11. [Epub ahead of print].
Physical Activity Preferences for People Living With Multiple Myeloma: A Qualitative Study.
Craike M et al. Cancer Nurs. 2016 Aug 16. [Epub ahead of print].
Multiple myeloma, immunotherapy and minimal residual disease.
Kusenda J et al. Neoplasma. 2016 Jul 29;(5). doi: 10.4149/neo_2016_501. [Epub ahead of print].
A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma.
Yusuf AA et al. Curr Med Res Opin. 2016 Aug 17:1-25. [Epub ahead of print].
Occupational exposure to polycyclic aromatic hydrocarbons and lymphatic and hematopoietic neoplasms: a systematic review and meta-analysis of cohort studies.
Alicandro G et al. Arch Toxicol. 2016 Aug 16. [Epub ahead of print].
Prevalence of symptoms in patients with multiple myeloma: A systematic review and meta-analysis.
Ramsenthaler C et al. Eur J Haematol. 2016 Aug 16. doi: 10.1111/ejh.12790. [Epub ahead of print].
Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.
Touati M et al. Support Care Cancer. 2016 Aug 15. [Epub ahead of print].
A global view on cancer incidence and national levels of the Human Development Index.
Fidler MM et al. Int J Cancer. 2016 Aug 13. doi: 10.1002/ijc.30382. [Epub ahead of print].
Multiple myeloma masquerading as severe seropositive rheumatoid arthritis with subcutaneous nodules and mononeuritis multiplex.
Edavalath S et al. Int J Rheum Dis. 2016 Aug 12. doi: 10.1111/1756-185X.12935. [Epub ahead of print].
The next generation of novel therapies for the management of relapsed multiple myeloma.
Gonsalves WI et al. Future Oncol. 2016 Aug 11. [Epub ahead of print].
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Usmani S et al. Oncologist. 2016 Aug 2. pii: theoncologist.2016-0104. [Epub ahead of print].
Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Varmavuo V et al. Ann Hematol. 2016 Oct;95(10):1653-9. doi: 10.1007/s00277-016-2772-1. Epub 2016 Aug 3.
IgE multiple myeloma: a new case report.
Gamundí Grimalt E et al. Clin Chem Lab Med. 2016 Jul 30. pii: /j/cclm.ahead-of-print/cclm-2016-0354/cclm-2016-0354.xml. doi: 10.1515/cclm-2016-0354. [Epub ahead of print].